重组人表皮生长因子软膏对烧伤患者血清表皮生长因子浓度的影响

目的:观察不同深度、不同面积烧伤创面对局部外用重组人表皮生长因子(rhEGF)软膏的吸收作用以及对血清EGF浓度的影响。方法:选择烧伤患者41例,局部外用rhEGF软膏治疗,每日换药一次。浅Ⅱ°创面患者于用药前和用药第4,7天;深Ⅱ°创面于用药前和用药后第7,14天,分别取患者静脉血清,采用放射免疫分析法测定患者各时间点血清中EGF浓度。结果:rhEGF软膏在试验浓度范围内,无论用药面积大小和用药时间长短其血清EGF水平均无明显变化,各时间点用药前后EGF血药浓度无显著差异(P>0.05);血清EGF浓度与创面深度和用药面积无明显的相关性。结论:rhEGF软膏局部外用,通过创面吸收的量甚微,体内无蓄积现象。     

猪胰岛素与重组人胰岛素的高效液相色谱分析

目的鉴别猪胰岛素与重组人胰岛素。方法采用C8、C1 8及常规孔径 (6～ 1 0nm)与大孔径 (30nm)色谱柱用梯度洗脱和等度洗脱对猪胰岛素与重组人胰岛素的分离方法进行研究。结果用梯度洗脱代替英国药典中的洗脱体系能达到相同的分离效果。结论用常规C1 8柱通过梯度洗脱可分离猪胰岛素与重组人胰岛素     

重组人表皮生长因子促进鼻内镜术后术腔上皮化

目的观察重组人表皮生长因子(rhEGF)对鼻内镜手术后术腔愈合的影响.方法对131例(235侧)施行鼻内镜手术分析的Ⅱ型2期、3期患者,随机分为两组,A组应用rhEGF,B组不用,随访4个月以上比较同期两组的治愈率.结果同期治愈率A组显著优于B组(P＜0.05).结论 rhEGF能促进术腔早日上皮化.     

内耳转基因表达的实验研究

目的　了解内耳转基因表达的可行性。方法　将人复制缺陷重组腺病毒基因(Adenoviruses ,Ad ,含大肠杆菌 β 半乳糖苷酶基因LacZ基因 ,Ad5 LacZ)经豚鼠耳蜗蜗窗接种到鼓阶外淋巴后 ,观察在不同时间、不同内耳组织中LacZ基因的表达 (X Gal染色 )及Ad对豚鼠声反应 (听性脑干反应 )、听毛细胞 (扫描电镜 )的影响。结果　Ad介导的LacZ基因在内耳组织中的表达至少可持续 4周 ,其中在螺旋神经节细胞表达稳定 ,Corti器、前庭囊斑、壶腹嵴的毛细胞等也有较强的表达。Ad未对豚鼠声反应 (≤ 80 0 0Hz)造成明显的损伤 ,除耳蜗底回外 ,其余各回未见明显的毛细胞缺失。结论　腺病毒载体可成功地将LacZ基因转导致豚鼠内耳组织中 ,并且未对豚鼠声反应 (低、中频 )及听毛细胞造成明显损伤 ,这对未来的内耳基因治疗研究可能具有重要的参考价值。     

人输卵管蛋白全长cDNA克隆及真核细胞中的表达

目的:克隆人输卵管蛋白(hOviductin)全长cDNA序列,真核细胞中表达,并了解hOviductin是否与大鼠卵母细胞结合。方法:构建人输卵管黏膜上皮细胞cDNA文库,以~(32)P标记的兔输卵管蛋白全长cDNA序列为探针,自文库中筛选hOviductin全长cDNA序列。将获得的hOviductin编码区cDNA序列插入pEGFP-N1真核表达载体,转染HeLa细胞,表达分泌重组的绿色荧光蛋白(EGFP)-hOviductin,并估量其浓度。激光扫描共聚焦显微镜下观察EGFP-hOviductin与大鼠卵巢的卵丘细胞-卵母细胞复合物(COC)或去除透明带后的裸卵的结合情况。结果:所构建的cDNA文库重组率为98.5％,滴度为1.1×10~6pfu/mL。克隆所得hOviductin全长cDNA约为2500 bp,Gen-Bank的登录号为AY189737。EGFP-hOviductin在条件培液中的浓度为0.236 nmol/L,能结合在去透明带的大鼠裸卵质膜外表面,而未见其与COC结合。结论:hOviductin能在HeLa细胞中表达分泌,其分泌产物可结合于大鼠裸卵质膜外表面。     

人子宫内膜细胞共培养体系对早期鼠胚体外发育的影响

目的:研究人子宫内膜共培养体系对早期鼠胚体外发育的影响及移植后的妊娠情况。方法:将2-细胞小鼠胚胎与人子宫内膜细胞进行体外共培养,对照组为无营养细胞的单纯培养液,每日在显微镜下观察胚胎的发育情况。将培养到囊胚期的胚胎移植回小鼠的子宫腔,观察着床情况。结果:共培养体系中68.3％的2-细胞胚胎发育至桑椹胚期,50.8％发育至囊胚期,囊胚的孵化率为36.7％,胚胎的着床率为25.0％。而对照组只有24.8％的2-细胞胚胎发育至桑椹胚期,11.4％到达囊胚期,且其中大部分为早期囊胚即停止发育。另外对照组细胞碎片出现早且多,卵裂球不均匀,胚形态差,移植后胚胎的着床率仅为3.1％。结论:人子宫内膜细胞共培养体系可以促进小鼠胚胎的体外发育,改善胚胎的质量,提高着床率。     

外阴癌中HPV感染与p53、MDM2表达的关系

目的 :探讨HPV6/ 11、16/ 18在外阴癌组织中的感染情况及与p5 3、MDM2蛋白表达的关系。方法 :用原位杂交法 (ISH)检测HPV6/ 11、16/ 18在 30例外阴癌、2 1例外阴上皮内瘤变 (VIN)及 10例外阴正常皮肤组织中的表达。同时用免疫组化SP法检测p5 3、MDM2蛋白的表达。结果 :HPV6/ 11、16/ 18在外阴癌、VIN中的阳性表达率分别为 60 % (18/30 )、33.33% (10 / 30 ) ,4 2 .86% (9/ 2 1)、2 8.5 7% (6/ 2 1) ,正常对照组没有表达。p5 3、MDM2蛋白在外阴癌、VIN、正常对照组中的阳性表达率分别为 63.33% (19/ 30 )、4 0 .0 0 % (12 / 30 ) ,4 7.62 %(10 / 2 1)、5 2 .38% (11/ 2 1) ,0 % (0 / 10 )、0 % (0 / 10 )。HPV6/ 11的表达在外阴癌组、VIN组与正常组差异有显著性 (P <0 .0 5 ) ,外阴癌组HPV16/ 18表达与正常组差异有显著性 (P <0 .0 5 )。外阴病变各组p5 3、MDM2与正常组差异有显著性 (P <0 .0 5 )。结论 :HPV6/ 11、HPV16/ 18、p5 3、MDM2蛋白在外阴组织的不同病变中表达均差异有显著性 ,在外阴癌的发生发展中HPV感染、p5 3突变和MDM2表达可能起一定的作用     

GnRH analogues as an adjuvant therapy for ovarian cancer patients.

OBJECTIVES: Lowering gonadotropin levels with gonadotropin-releasing hormone (GnRH) analogues in patients with ovarian cancer remains open to debate. The aim of this study was to assess the results of treatment in stage III and stage IV ovarian cancer patients who had surgery supplemented with chemotherapy, radiotherapy, and GnRH analogues. Gonadotropin levels were monitored during treatment. METHODS: The study group comprised 69 patients aged 27-70 years, stratified according to the type of treatment. The overall disease-free, 5-year survival rates and the frequency of remissions were analyzed. Hormonal tests [follicle-stimulating hormone (FSH) and luteinizing hormone (LH)] were performed in 58 patients. Associations were checked between gonadotropin levels, clinical findings, and survival. The results were statistically compared. RESULTS: Statistically significant differences were noted when chemotherapy was supplemented with GnRH analogues and/or radiotherapy. Administration of GnRH analogues resulted in significantly lower levels of LH than of FSH. Levels of FSH were significantly lower in patients surviving at least 5 years or in complete remission at the time of this study. CONCLUSIONS: Combined therapy can produce favorable results in late-stage ovarian cancer, and GnRH analogues have an important role in treatment strategy.     

FOLFOX方案治疗30例晚期胃癌疗效观察

目的：观察每二周高剂量亚叶酸钙（CF）／氟脲嘧啶（5－FU）与草酸铂（L－OHP）方案（FOLFOX方案）治疗晚期胃癌的临床疗效和毒副反应。方法：采用高剂量CF／5－FU／L－OHP深静脉输注方案（CF200mg.m^2-1.d^-1，静滴2小时，第1、2天；5-FU400mg.m^2-1.d^-1,静推，第1天，5－FU1600mg.m^2-1.d^-1，静滴22小时，第1、2天；L－OHP130mg.m^2-1.d^-1，静脉输注4小时，第1天），化疗方案以14天为1周期，重复4周期后间隔1个月评定疗效。结果：全组30例，总有效率为53．3％，18例初治组的有效率为61．11％，其中CR1例。12例复治组的有效率为41．7％，初治组中位缓解期为5个月。复治组的中位缓解期为3个月。Ⅱ、Ⅲ度口腔炎发生率为26．7％，7例出现手足综合征，血液学毒性轻微。结论：每二周高剂量CF／5－FU／L－OHP方案是治疗晚期胃癌有效安全的化疗方案。     

Hydrolysis kinetics of propylene glycol monomethyl ether acetate in rats in vivo and in rat and human tissues in vitro.

The kinetic equivalency of propylene glycol monomethyl ether (PGME), derived from propylene glycol monomethyl ether acetate (PGMEA), as well as the parent compound (PGME) following intravenous administration to Fischer 344 rats was evaluated. In addition, in vitro hydrolysis rates of PGMEA in blood and liver tissue from rats and humans were determined. The blood kinetics were determined following iv administration to rats of PGME and PGMEA of low [10 and 14.7 mg/kg body weight (bw)] or high (100 and 147 mg/kg) equimolar dosages of PGME and PGMEA, respectively. The blood time courses of PGME elimination for both dosages of both compounds were identical. Half-lives of PGMEA elimination following iv administration of 14.7 or 147 mg PGMEA/kg bw were calculated to be 1.6 and 2.3 min, respectively. Rat and human in vitro hydrolysis rates of PGMEA were determined by incubation of 5 or 50 microg PGMEA/ml in whole blood or liver homogenate. The rate of loss of PGMEA was more rapid in rat blood than in human blood, with hydrolysis half-lives of 36 and 34 min in human blood and 16 and 15 min in rat blood for the 5 and 50 microg/ml concentrations of PGMEA, respectively. In contrast the rate of loss of PGMEA in human and rat liver homogenate incubations was similar, 27-30 min and 34 min, respectively. These data demonstrate the rapid hydrolysis of PGMEA in vivo to its parent glycol ether, PGME and that, once hydrolyzed, the kinetics for PGME derived from PGMEA are identical to that for PGME. This study supports the use of the toxicological database on PGME as a surrogate for PGMEA.